Author:
Camidge D. Ross,Dziadziuszko Rafal,Peters Solange,Mok Tony,Noe Johannes,Nowicka Malgorzata,Gadgeel Shirish M.,Cheema Parneet,Pavlakis Nick,de Marinis Filippo,Cho Byoung Chul,Zhang Li,Moro-Sibilot Denis,Liu Ting,Bordogna Walter,Balas Bogdana,Müller Barbara,Shaw Alice T.
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference16 articles.
1. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study;Ou;J Clin Oncol,2016
2. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial;Shaw;Lancet Oncol,2016
3. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer;Peters;N Engl J Med,2017
4. EML4-ALK variants: biological and molecular properties, and the implications for patients;Sabir;Cancers (Basel),2017
5. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007
Cited by
342 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献